Menu Close
Close
Apply Now
Apply Now →

Stem Cell Therapy for Sexual Dysfunction

Regenerative Medicine for Sexual Health and Performance

UC-MSC-derived exosome protocols are being studied for their role in the biological factors underlying sexual function, vascular health, peripheral nerve signaling, and tissue quality. As a stem cell treatment for erectile dysfunction and related conditions, every protocol is physician-supervised and requires clinical evaluation.

Start your evaluation

Targeting the Underlying Biological Factors of Sexual Dysfunction

Sexual function depends on several systems working together: blood flow, nerve signaling, hormonal environment, and tissue health. Regenerative medicine for sexual health is studied for its potential effect on those underlying factors rather than on the symptom alone.

How It Works

UC-MSC-derived exosomes are nanoscale vesicles that carry proteins, growth factors, and signaling RNA involved in intercellular communication. In the context of sexual health, they are being studied for their potential to support vascular function, peripheral nerve signaling, and mucosal and erectile tissue health. Individual responses vary and are evaluated during the clinical consultation process.

Vascular Support

UC-MSC-derived exosomes carry angiogenic signaling factors associated with endothelial function and microvascular health — biological contributors to erectile capacity and genital arousal.

Nerve Signaling Support

Peripheral nerve health is a recognized contributor to sexual sensitivity and function. Exosomes are being studied for their potential to support neural signaling pathways relevant to sexual responsiveness.

Hormonal Environment

Chronic inflammation and hormonal change can affect sexual function. UC-MSC therapies may support tissue homeostasis in ways that contribute to a more favorable biological environment.

Tissue Health

Exosome-mediated signaling is studied for its potential relevance to the elasticity and structural integrity of genital tissue.

Conditions Being Studied with UC-MSC and Exosome Therapies

Sexual dysfunction has many causes, and the cause matters more than the symptom when determining whether a regenerative protocol is appropriate. The conditions below represent areas of clinical investigation. Suitability is determined through physician evaluation.
As a stem cell therapy for erectile dysfunction approach, UC-MSC and exosome protocols are studied primarily for their vascular and neural signaling effects. ED is frequently vascular in origin, which is why it is often an early indicator of broader cardiovascular disease, and why evaluation includes cardiovascular and metabolic health rather than the symptom in isolation. Patients with diabetes-related or age-related vascular ED are among those most commonly evaluated.
Stem cell therapy for Peyronie's disease research focuses on fibrotic signaling — the plaque formation that characterizes the condition. Evidence is early-stage. Disease stage matters considerably, and candidacy is assessed conservatively.
Sexual Dysfunction Nerve injury following prostate surgery is a well-defined cause of ED with limited conventional options beyond PDE5 inhibitors and devices. The neural-signaling mechanism under study is directly relevant, which makes this one of the more clinically coherent applications on this page.

Age-related change in sexual function often reflects vascular and inflammatory change rather than a discrete diagnosis. These patients are typically evaluated in the context of a broader healthy aging protocol, see Healthy Aging & Longevity.

Protocols at OmniStem are designed to engage the body’s natural repair signaling, with outcomes assessed individually. For supporting scientific references, visit our Resource Center.

How This Compares to Other Sexual Health Treatments

Most patients have already tried at least one conventional option. The distinction is what each approach acts on:

Approach What it does Typical limitation
PDE5 inhibitors (sildenafil, tadalafil) Enhance blood flow on demand Effective for many patients. Acts per dose rather than on underlying vascular health
Testosterone replacement therapy Corrects documented hormonal deficiency Relevant only where deficiency is confirmed. Requires ongoing management
Shockwave therapy (Li-ESWT) Acoustic energy intended to stimulate vascular response Evidence is mixed. Multiple sessions required
PRP / platelet-based injection Concentrated autologous platelets for local signaling Signaling is limited to the patient's own platelet profile
UC-MSC + exosome protocols Studied for effects on vascular, neural, and tissue signaling Investigational. Physician evaluation required to confirm candidacy

This is not positioned as a replacement for treatment prescribed by a urologist or primary care physician. Patients continue prescribed medication unless their treating physician directs otherwise.

Am I a candidate? Candidacy depends on the underlying cause. ED with a primarily psychological or medication-induced cause, or ED reflecting untreated cardiovascular or metabolic disease, may call for a different path entirely, and the medical team will say so. Because ED can be the first visible sign of vascular disease, evaluation looks at cardiovascular and metabolic health, not just the presenting symptom. Some patients who inquire are told a protocol isn’t appropriate for their situation.

Confidential Evaluation

Sexual health inquiries are reviewed by the medical team under the same confidentiality standards as every other clinical case at OmniStem. Your information is handled in accordance with HIPAA privacy standards, and the initial review is a medical conversation.

Why Patients Travel for These Protocols

Allogeneic UC-MSC and exosome protocols of this kind are not currently available through US clinics. OmniStem’s facility in Punta Cana, Dominican Republic is approximately 90 minutes by air from Miami, with direct flights from major Eastern US cities.

Frequently Asked Questions

Sexual dysfunction can result from multiple factors, including reduced blood flow, nerve impairment, hormonal imbalance, or tissue degeneration. UC-MSCs and their exosomes are being studied for their potential to support circulation, nerve health, and inflammatory regulation. By releasing growth factors and signaling molecules, these therapies may support tissue function. All protocols require individual medical evaluation prior to administration.

Regenerative approaches are investigational and are being studied in men and women with conditions such as erectile dysfunction, reduced libido, Peyronie's disease, and menopause-related changes affecting sexual health. Each case requires individual assessment, as responses vary depending on age, health status, and underlying cause.

Individual responses vary significantly. In some cases, patients have reported early improvements in sensitivity or function within weeks of treatment, while others experience gradual changes over several months. These are individual accounts and are not predictive of outcomes for other patients. Because regenerative therapies engage natural repair processes, results are not immediate and often continue to evolve over 4–8 months following treatment.

UC-MSC and exosome-based therapies have shown favorable safety profiles in studies conducted under controlled laboratory and clinical protocols. Because the cells are ethically sourced and carefully processed, the risk of immune rejection is considered low. Reported side effects are generally mild and short-lived, such as local soreness or temporary inflammation. As with any medical therapy, rare complications are possible. A full medical evaluation and monitoring are performed for every patient.

No. PDE5 inhibitors such as sildenafil and tadalafil are approved medications that work on demand by enhancing blood flow, and they remain appropriate first-line treatment for many patients. UC-MSC and exosome protocols are investigational and are studied for a different purpose: the vascular, neural, and tissue biology underlying sexual function. Some patients explore a regenerative protocol when medication is insufficient, poorly tolerated, or not indicated. That decision belongs with your treating physician.

Yes. Sexual health inquiries are handled under the same confidentiality standards as every other clinical case, in accordance with HIPAA privacy standards. Your information is reviewed by the medical team and used to determine clinical suitability.

AdobeStock 583040304

A Confidential Medical Review

Your case is reviewed by a physician under HIPAA privacy standards.

Start Your Evaluation

Your case.

In our hands.

Within 48 hours.

A physician on the OmniStem medical team will review your clinical profile and prepare an initial assessment. What follows is a medical conversation.

Your clinical profile   2 MIN

A brief summary of your health context. The medical team uses this to prepare before your first conversation.

Physician review   48 H

Dr. Montoya or a member of the medical team evaluates your profile individually.

A clinical conversation

Your history, your priorities, and what a protocol designed around your clinical profile might include.

No obligation

The case review is informational. The only timeline that matters is yours.

Step 1

A few questions to begin

These help the medical team understand whether OmniStem’s protocols are appropriate for your situation before we speak.

Check Access 2.0

What is your primary area of health concern?

Select up to three options that best describe your concerns.

Begin Your Clinical Evaluation

UC-MSC-derived exosome protocols designed to support sexual tissue health and vascular function, administered under physician supervision and individualized to your clinical profile.
Start your evaluation